4.8 Article

Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis

期刊

MOLECULAR PSYCHIATRY
卷 19, 期 8, 页码 880-889

出版社

SPRINGERNATURE
DOI: 10.1038/mp.2013.126

关键词

ADHD; dopamine transporter; genetics; meta-analysis; PET; SPECT

资金

  1. National Institutes of Health (NIH)
  2. Shire
  3. Alcobra
  4. Otsuka
  5. McNeil
  6. Janssen
  7. Novartis
  8. Pfizer
  9. Eli Lilly
  10. Shire Laboratories Inc
  11. Shire Laboratories Inc, Cephalon
  12. Eli Lilly Company
  13. McNeil Pharmaceutical
  14. Novartis Pharmaceuticals
  15. Department of Defense
  16. Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing
  17. Harvard University
  18. Navidea Biopharmaceuticals
  19. Prexa Pharmaceuticals
  20. NIDA
  21. CDC
  22. NIDA Council
  23. Hilton Foundation and Convecta
  24. Elminda
  25. Fundacion Areces
  26. Medice Pharmaceuticals
  27. Spanish Child Psychiatry Association
  28. Abbott
  29. Alza
  30. AstraZeneca
  31. Bristol Myers Squibb
  32. Celltech
  33. Cephalon
  34. Eli Lilly and Co.
  35. Esai
  36. Glaxo
  37. Gliatech
  38. Merck
  39. NARSAD
  40. New River
  41. NICHD
  42. NIMH
  43. Noven
  44. Neurosearch
  45. Organon
  46. Pharmacia
  47. Prechter Foundation
  48. Stanley Foundation
  49. UCB Pharma, Inc.
  50. Wyeth

向作者/读者索取更多资源

Much psychiatric genetic research has focused on a 40-base pair variable number of tandem repeats (VNTR) polymorphism located in the 30-untranslated region (30UTR) of the dopamine active transporter (DAT) gene (SLC6A3). This variant produces two common alleles with 9- and 10-repeats (9R and 10R). Studies associating this variant with in vivo DAT activity in humans have had mixed results. We searched for studies using positron emission tomography (PET) or single-photon emission computed tomography (SPECT) to evaluate this association. Random effects meta-analyses assessed the association of the 30UTR variant with DAT activity. We also evaluated heterogeneity among studies and evidence for publication bias. We found twelve studies comprising 511 subjects, 125 from PET studies and 386 from SPECT studies. The PET studies provided highly significant evidence that the 9R allele was associated with increased DAT activity in human adults. The SPECT studies were highly heterogeneous. As a group, they suggested no association between the 30UTR polymorphism and DAT activity. When the analysis was limited to the most commonly used ligand, [123I] b-CIT, stratification by affection status dramatically reduced heterogeneity and revealed a significant association of the 9R allele with increased DAT activity for healthy subjects. In humans, the 9R allele of the 30UTR polymorphism of SLC6A3 regulates dopamine activity in the striatal brain regions independent of the presence of neuropsychiatric illness. Differences in study methodology account for the heterogeneous results across individual studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据